Sevelamer Carbonate Tablet, Film Coated
Product Images NDC 70710-2170

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sevelamer Carbonate (NDC 70710-2170). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (C18f24f4 6578 43b0 9dda 6581e7137ffd 01)

Chemical structure of sevelamer carbonate, showing the polymeric form with labeled functional groups including NH3+, HCO3-, NH, and OH sites, consistent with its polymeric amine and carbonate composition.*

FDA Label Image

Image (C18f24f4 6578 43b0 9dda 6581e7137ffd 02)

A forest plot chart comparing the effects of Sevelamer carbonate versus placebo across different subgroups and overall. The chart shows the number of subjects, least squares mean differences with 95% confidence intervals, and a vertical line for no effect. Subgroups include screening BSA, baseline serum phosphorus, age, and dialysis status.*

FDA Label Image

Image (C18f24f4 6578 43b0 9dda 6581e7137ffd 03)

A line graph depicting the percentage of patients with at least a twofold reduction in serum phosphorus, comparing Sevelamer Hydrochloride to an active control. The horizontal axis shows the reduction in serum phosphorus (mg/dL), with markers for increased and reduced levels, while the vertical axis shows the percentage of patients achieving this reduction.*

FDA Label Image

Image (C18f24f4 6578 43b0 9dda 6581e7137ffd 04)

A line graph showing the change in phosphorus levels from baseline over a 52-week study period. The x-axis represents study weeks from 0 to 52, and the y-axis represents the phosphorus change from baseline ranging from -5 to 2. Two treatment groups are compared: Sevelamer Hydrochloride and an active control, with data points and trend lines illustrating their phosphorus changes over time.*

FDA Label Image

Bottle-270-pdp (C18f24f4 6578 43b0 9dda 6581e7137ffd 05)

Label for Sevelamer Carbonate Tablets 800 mg, film-coated, oral dosage form. The label includes active ingredient and inactive ingredients information, storage instructions, and package count of 270 tablets. Distributed by Zydus Pharmaceuticals USA Inc., Pennington, NJ. The label also displays the NDC number 70710-2170 and a barcode.*

FDA Label Image

Bottle-30-pdp (C18f24f4 6578 43b0 9dda 6581e7137ffd 06)

Label for Sevelamer Carbonate Tablets 800 mg film-coated tablets, distributed by Zydus Pharmaceuticals USA Inc. The label includes storage instructions, inactive ingredients, and states a quantity of 30 tablets per container. The product is for oral use and is marked Rx only. A barcode and product NDC 70710-2170-3 are also visible.*

FDA Label Image

180-c (C18f24f4 6578 43b0 9dda 6581e7137ffd 07)

Label for Sevelamer Carbonate Tablets, 800 mg, film-coated tablets supplied in a package of 180 tablets. The label includes active ingredient details, storage instructions, and distribution information by Zydus Pharmaceuticals USA Inc. It displays the NDC 70710-2170 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.